Replies to post #789 on Vascular Biogenics Ltd (VBLT)

[wcopeland]

gr8db8: Yes, that is what I am referencing. Also, yes, I am assuming VB111 will not be included in the partnership.

But I just was asking for more clarity on how good Ph3 VB111 translates into "leverage". Theoretically, yes, good data will boost VBL's confidence, but will that really materialize into a better deal? I doubt it.

If pharma is looking for a NASH partner, they will be moved by several things (ie. how many other companies are pursuing VBL's NASH and how solid was the NASH data). I do not see positive VB111 interim data being one of those things that really moves the partnership terms - unless the pharma really believes in VBL's scientific discovery process.